Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02227251 · ClinicalTrials.gov registry record · Phase 2

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Karyopharm Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
244
Enrollment target
20
Study locations

NCT02227251 is a Phase 2 study of Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Karyopharm Therapeutics. The registered enrollment target is 244 participants, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02227251, a Phase 2 study of Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Karyopharm Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
244 participants
Enrollment target
20
Study locations

Study Summary

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.

Conditions Studied

Diffuse Large B Cell Lymphoma

Interventions

  • DRUG Selinexor

Study Locations (20)

Massachusetts

  • Dana Farber Cancer Institute - Boston
  • Tufts Medical Center - Boston
  • Lahey Clinic - Burlington
  • University of Massachusetts Medical School - Worcester

New York

  • Clinical Research Alliance - Lake Success
  • New York Presbyterian Hospital/ Cornell Medical College - New York
  • Stony Brook University Hospital - Stony Brook

Ohio

  • Gabrail Cancer Center - Canton
  • Cleveland Clinic Foundation - Cleveland
  • University Hospitals Seidman Cancer Center - Cleveland

California

  • University of California San Francisco - San Francisco
  • University of California Los Angeles (UCLA) - Santa Monica

Illinois

  • University of Chicago - Chicago
  • Robert H. Lurie Comprehensive Cancer Center/Northwestern University - Chicago

Arizona

  • UACC Arizona - Tucson

Florida

  • Boca Raton Cancer Research Medical Center - Plantation

Kentucky

  • Norton Cancer Institute - Louisville

Trial Details

FieldValue
Enrollment Target 244 participants
Start Date 2014-11
Est. Completion 2027-11
Phase Phase 2

Sponsor

Karyopharm Therapeutics

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02227251

The ClinicalTrials.gov registry entry for NCT02227251 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (12% higher). The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Selinexor is the first listed.

NCT02227251 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Massachusetts, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT02227251 about?

NCT02227251 is a clinical study titled "Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)". A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.

What is the current status of trial NCT02227251?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2014-11. Estimated completion is 2027-11.

What conditions does trial NCT02227251 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.

What interventions are being tested in trial NCT02227251?

The interventions under investigation include: Selinexor (DRUG).

Who is sponsoring clinical trial NCT02227251?

This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02227251 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.